Search Bar & Filters
Found 20 Actively Recruiting clinical trials
Actively Recruiting
Researchers are comparing two treatment combinations for adults with advanced nonsquamous non-small cell lung cancer NSCLC that is stage IV or advanced stage IIIBC, specifically with a KRAS p.G12C mutation and no PD-L1 expression. The study evaluates progression-free survival and overall survival between participants receiving sotorasib with chemotherapy and those receiving pembrolizumab with chemotherapy. This is a phase 3, randomized, open-label study aiming to find which frontline therapy might better manage this type of lung cancer. Participants are randomly assigned to one of two groups one group receives sotorasib orally combined with carboplatin and pemetrexed chemotherapy, and the other group receives pembrolizumab given intravenously combined with the same chemotherapy agents. Treatments are given as front-line therapy for their cancer. The study measures the effects of these combinations over time, including tumor response and quality of life changes. During the study, participants will be closely monitored for progression-free survival, overall survival, and other outcomes related to tumor response and quality of life through questionnaires. Researchers will track treatment-emergent adverse events, vital signs, and lab tests to evaluate safety. The study includes follow-up assessments for up to approximately 5.5 years, allowing comprehensive evaluation of long-term outcomes and side effects. Participant involvement includes regular visits for treatment administration and assessments throughout the study period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of TAR-210 compared to intravesical chemotherapy in treating high-risk non-muscle-invasive bladder cancer HR-NMIBC. This Phase 3 study focuses on disease-free survival, which is the length of time participants live without signs or symptoms of cancer returning or worsening. The study targets patients with specific FGFR genetic alterations who have previously received BCG treatment but remain at high risk for cancer recurrence. Participants are randomly assigned to one of two groups Group A will have the investigational drug TAR-210 placed inside the bladder on Day 1 and continue treatment for about two years. Group B will receive intravesical chemotherapy with either mitomycin C or gemcitabine weekly for 4 to 6 doses, followed by monthly maintenance for up to one year, with an optional second year of maintenance depending on the investigators decision. All treatments are delivered directly into the bladder. Throughout the study, participants will have regular assessments including monitoring for cancer recurrence, progression, and overall survival for up to five years. Researchers will collect safety data such as adverse events and changes in laboratory tests and vital signs. Quality of life will be measured using specific questionnaires at multiple time points. The study involves ongoing visits and evaluations to closely observe treatment effects and participant well-being over the long term.
Actively Recruiting
Researchers are evaluating the investigational drug PF-06821497 mevrometostat combined with enzalutamide compared to enzalutamide alone in men with metastatic castration-resistant prostate cancer mCRPC who have not previously received certain systemic treatments. This global, multicenter, randomized Phase 3 study focuses on participants who have mCRPC but have only received androgen deprivation therapy or first-generation anti-androgen agents, excluding prior treatment with androgen receptor signaling inhibitors such as enzalutamide or abiraterone. Participants are randomly assigned to one of two groups one receiving PF-06821497 twice daily plus enzalutamide once daily, and the other receiving a placebo twice daily plus enzalutamide once daily. The study includes several phases screening, randomization, treatment, safety follow-up, and long-term follow-up. Treatment is continuous oral dosing during the treatment phase. Throughout the study, participants will undergo regular assessments including scans, laboratory tests, and patient-reported questionnaires to measure outcomes such as radiographic progression-free survival, overall survival, pain progression, prostate specific antigen levels, and quality of life. Safety is monitored continuously, and follow-up can last up to approximately five years after randomization to evaluate long-term effects and treatment impact.
Actively Recruiting
Researchers are conducting a Phase III international trial to study the effects and safety of androgen deprivation therapy ADT with or without darolutamide in men newly diagnosed with metastatic prostate cancer who have vulnerable functional abilities. This study specifically includes patients who have not chosen treatment with docetaxel or other androgen receptor pathway inhibitors. The goal is to evaluate how these treatments impact disease progression and patient health over time. Participants will be randomly assigned to one of two groups one receiving ADT plus darolutamide 600 mg taken orally twice daily, and the other receiving ADT plus a placebo taken with the same schedule. Treatment will continue until imaging shows disease progression or until the patient or doctor decides to stop for reasons such as side effects or other health issues. After stopping treatment, patients will enter a follow-up phase lasting up to 10 years to monitor survival, further treatments, and any ongoing or new side effects. During the study, participants will undergo regular assessments including imaging scans to check for cancer progression, blood tests, evaluations of urinary symptoms, and quality of life questionnaires. Researchers will track outcomes like progression-free survival, overall survival, symptom changes, and adverse events. Monitoring visits will occur periodically both during treatment and follow-up to gather comprehensive data on health status and treatment effects.
Actively Recruiting
Non-muscle-invasive bladder cancer NMIBC is a type of bladder tumor that affects the inner lining of the bladder without invading the muscle layer. This research aims to collect and analyze real-world data on how NMIBC is managed and followed up in clinical practice across France. The study seeks to assess the performance of urine tests used to detect tumor recurrence and to understand variations in treatment and patient outcomes. The study is observational and involves collecting medical data from patients being monitored for NMIBC, including results from urine biomarker tests done before biopsies or resections. Urologists participating in the French Urology Association will record findings from regular bladder endoscopic exams and urine test results during routine care visits. Data analysis will focus on the accuracy of urine tests in predicting tumor recurrence and how this varies by tumor characteristics and prior treatments. Participants will have their medical history, treatments, and urine test results entered into a registry at enrollment. During follow-up visits scheduled as part of their personalized care, data on bladder exams and urine tests will be collected. Researchers will evaluate outcomes such as recurrence-free survival and the diagnostic value of urine biomarkers over a five-year period. The study plans to include around 8,000 patients over six years to improve understanding of NMIBC management and follow-up.
Actively Recruiting
Researchers are investigating treatments for patients with hormone receptor-positive, HER2 low or ultralow metastatic breast cancer who are undergoing first-line therapy with a CDK46 inhibitor combined with an aromatase inhibitor or fulvestrant. This open-label, multicenter phase II study focuses on patients whose tumor DNA remains detectable in their blood after four weeks of standard therapy, aiming to evaluate progression-free survival using trastuzumab deruxtecan T-DXd treatment. Patients first enter a screening phase to confirm the presence of circulating tumor DNA after starting standard treatment. Those with persistent tumor DNA are enrolled in the treatment phase, where they receive trastuzumab deruxtecan as an intravenous injection every three weeks at a dose of 5.4 mgkg. This single-group study evaluates how long patients live without disease progression while receiving the study drug. Participants undergo regular assessments including laboratory tests and imaging to monitor their disease status and safety during the study. Researchers measure progression-free survival as the primary outcome, along with overall survival, response rates, duration of response, clinical benefit, time to response, and treatment toxicity up to five years. Participants are followed for outcomes and safety throughout the study period, which may last several years.
Actively Recruiting
Researchers are investigating the use of endoscopic surgery as a less invasive alternative to traditional lumbar spine fusion for patients with spinal stenosis and spondylolisthesis. This approach aims to decompress the lumbar spine while preserving its natural function and stability, potentially reducing the need for spinal fusion. The study explores whether endoscopic techniques can lower the rate of more invasive surgical interventions in this population. The study focuses on patients who require spinal decompression surgery and are considered for endoscopic procedures. It observes outcomes related to these minimally destructive surgical methods without introducing experimental drugs or devices. The main goal is to evaluate the rate of surgical reintervention within one year after the initial endoscopic surgery. Participants will be monitored over time to assess if further surgical procedures are needed. Researchers will review medical imaging and clinical data to understand the effectiveness of endoscopic decompression in avoiding fusion surgery. The study involves adults 18 years and older and tracks outcomes related to surgical reintervention during the follow-up period, with participation potentially lasting up to several years.
Actively Recruiting
Researchers are evaluating whether the EMOCARE emotional monitoring software provides consistent results compared to standard questionnaires used to assess emotional states in patients with mild to moderately severe depressive episodes. This study aims to understand how well EMOCARE matches tools like PHQ-9, MADRS, GAD-7, BDI-II, and EQ-5D-5L, and to learn about any medical issues participants may experience when using this passive monitoring software. The study focuses on outpatients with major depressive disorder who use digital devices regularly. Participants will install the EMOCARE software on a smartphone, computer, or similar device and can activate or deactivate it during a six-week follow-up period. They will attend two scheduled visits at the centerone at the start and one six weeks laterto complete questionnaires and be interviewed by a doctor. Additionally, participants will complete questionnaires independently at home two and four weeks after the first appointment. A phone call from the doctor will take place three weeks after the initial visit to check on how participants are feeling. Participants will also keep a diary of symptoms, medical consultations, and any medication changes. Throughout the study, researchers will collect and compare scores from EMOCARE and various questionnaires at multiple time points, including baseline, two, four, and six weeks. They will monitor the acceptability of the device, adverse events, and changes in depression severity. The main outcomes measured are changes in EMOCARE scores and PHQ-9 scores from baseline to six weeks. The total participation duration is six weeks, with regular monitoring and assessments to understand emotional states and device use.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of ficerafusp alfa combined with pembrolizumab compared to placebo with pembrolizumab in adults with first-line PD-L1-positive, recurrent or metastatic Head and Neck Squamous Cell Carcinoma HNSCC. This study targets two cancer drivers, EGFR and TGF-beta, to address tumor growth and spread. It includes phase 2 to find the best dose and phase 3 to compare treatment outcomes. In phase 2, participants are randomly assigned to one of three groups ficerafusp alfa 1500 mg weekly plus pembrolizumab every three weeks, ficerafusp alfa 750 mg weekly plus pembrolizumab every three weeks, or placebo weekly plus pembrolizumab every three weeks. Phase 3 uses the optimal dose of ficerafusp alfa with pembrolizumab versus placebo with pembrolizumab in a 21 ratio. Treatments continue with scheduled dosing during each phase. Participants undergo regular assessments including scans to measure tumor response by RECIST 1.1 criteria, safety monitoring for side effects, and quality of life questionnaires. The study tracks objective response rate, overall survival, progression-free survival, and other measures over up to three years. Safety is closely monitored for treatment-related adverse events during and after therapy. Total participation may last several years depending on treatment and follow-up.
Actively Recruiting
Researchers are studying the impact of Ziwig Endotest4, a medical device that identifies endometriosis from a saliva sample using advanced sequencing and algorithms. This non-invasive test aims to reduce diagnostic delays and guide treatment strategies for women with suspected endometriosis. The study focuses on how the Endotest results affect patients quality of life, emotional experiences, coping strategies, and care pathways, areas not yet fully documented. Participants are women aged 18 to 43 who have been prescribed the Endotest. The study is observational and involves completing validated self-report questionnaires, such as EHP 56 and RAND-36, at the start, six months, and twelve months. Clinical data will also be collected from medical records to track the impact of the Endotest on patient care, including tests, treatments, and procedures like laparoscopy, as well as on assisted reproductive technology journeys. During the study, participants will complete questionnaires at baseline, six months, and twelve months to assess quality of life, anxiety levels, pelvic sensitivity, and adaptation strategies. The research team will monitor the patients care pathways and compare outcomes based on Endotest results across different countries. The study aims to provide valuable, generalizable data over an average follow-up period of one year to inform both clinicians and patients.
1-10 of 20
1